Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, as quick as it may have been, because that familiar routine of meetings, deadlines, and what-not has predictably returned. Our short person, in fact, concurred that these developments are inevitable while trudging off to the local schoolhouse. As for us, we are coping by firing up the coffee kettle and quaffing cups of stimulation. Almond toffee is on the menu today. You know the drill: grab your own cup. Meanwhile, here are some tidbits to help you along. Hope your day goes well and, as always, we encourage you to keep in touch …

The Food and Drug Administration approved a new Teva Pharmaceutical (TEVA) migraine treatment that the company has been banking on to help revive its fortunes, Reuters explains. The wholesale price of the drug, Ajovy, is $575 a month, the same as Aimovig, a similar monthly injection sold by Amgen (AMGN) and Novartis (NVS) that has been available in the U.S. since May. The move comes as Teva cuts its workforce and closes or sells factories in order to lower debt, which is now about $28.4 billion and had ballooned after the company bought the Actavis generics business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!